Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy: Long-term Follow-up of a 2-Year Randomized Clinical Trial
Reads0
Chats0
TLDR
Dose reduction/discontinuation of antipsychotics during the early stages of remitted FEP shows superior long-term recovery rates compared with the rates achieved with MT, the first study showing long- term gains of an early-course DR strategy in patients with remitting FEP.Abstract:
Importance Short-term outcome studies of antipsychotic dose-reduction/discontinuation strategies in patients with remitted first-episode psychosis (FEP) showed higher relapse rates but no other disadvantages compared with maintenance treatment; however, long-term effects on recovery have not been studied before. Objective To compare rates of recovery in patients with remitted FEP after 7 years of follow-up of a dose reduction/discontinuation (DR) vs maintenance treatment (MT) trial. Design Seven-year follow-up of a 2-year open randomized clinical trial comparing MT and DR. Setting One hundred twenty-eight patients participating in the original trial were recruited from 257 patients with FEP referred from October 2001 to December 2002 to 7 mental health care services in a 3.2 million-population catchment area. Of these, 111 patients refused to participate and 18 patients did not experience remission. PARTICIPANTS After 7 years, 103 patients (80.5%) of 128 patients who were included in the original trial were located and consented to follow-up assessment. Intervention After 6 months of remission, patients were randomly assigned to DR strategy or MT for 18 months. After the trial, treatment was at the discretion of the clinician. Main outcomes and measures Primary outcome was rate of recovery, defined as meeting the criteria of symptomatic and functional remission. Determinants of recovery were examined using logistic regression analysis; the treatment strategy (MT or DR) was controlled for baseline parameters. Results The DR patients experienced twice the recovery rate of the MT patients (40.4% vs 17.6%). Logistic regression showed an odds ratio of 3.49 (P = .01). Better DR recovery rates were related to higher functional remission rates in the DR group but were not related to symptomatic remission rates. Conclusions and relevance Dose reduction/discontinuation of antipsychotics during the early stages of remitted FEP shows superior long-term recovery rates compared with the rates achieved with MT. To our knowledge, this is the first study showing long-term gains of an early-course DR strategy in patients with remitted FEP. Additional studies are necessary before these results are incorporated into general practice. Trial registration isrctn.org Identifier: ISRCTN16228411.read more
Citations
More filters
Journal ArticleDOI
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders
Cherrie Galletly,David J. Castle,Frances Dark,Verity Humberstone,Assen Jablensky,Eoin Killackey,Jayashri Kulkarni,Patrick D. McGorry,Olav Nielssen,Nga Tran +9 more
TL;DR: This guideline takes a holistic approach, addressing all aspects of the care of people with schizophrenia and related disorders, not only correct diagnosis and symptom relief but also optimal recovery of social function, and uses a clinical staging model as a framework for recommendations regarding assessment, treatment and ongoing care.
Journal ArticleDOI
Improving outcomes of first-episode psychosis: an overview
TL;DR: To improve outcomes of a complex, heterogeneous syndrome such as psychosis, it is necessary to globally adopt complex models integrating a clinical staging framework and coordinated specialty care programmes that offer pre‐emptive interventions to high‐risk groups identified across the early stages of the disorder.
Journal ArticleDOI
Emerging Perspectives From the Hearing Voices Movement: Implications for Research and Practice
TL;DR: The historical growth and influence of the HVM is discussed, and it is suggested that the involvement of voice-hearers in research and a greater use of narrative and qualitative approaches are essential.
Journal ArticleDOI
Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?
Robin M. Murray,Diego Quattrone,Sridhar Natesan,Johannas Van Os,Merete Nordentoft,Oliver D. Howes,Marta Di Forti,David Taylor +7 more
TL;DR: The wise psychiatrist should regularly review the benefit to each patient of continuing prophylactic antipsychotics against the risk of side-effects and loss of effectiveness through the development of supersensitivity of the dopamine D2 receptor.
Journal ArticleDOI
What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?
TL;DR: The critical appraisal of the literature indicates that, although chronic antipsychotic use can be associated with undesirable neurologic and metabolic side effects, the evidence supporting its long‐term efficacy and effectiveness, including impact on life expectancy, outweighs the evidence against this practice, overall indicating a favorable benefit‐to‐risk ratio.
References
More filters
Journal ArticleDOI
The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia
TL;DR: Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.
Journal ArticleDOI
The Dopamine Hypothesis of Schizophrenia: Version III—The Final Common Pathway
Oliver D. Howes,Shitij Kapur +1 more
TL;DR: The dopamine hypothesis of schizophrenia-version III is synthesized into a comprehensive framework that links risk factors, including pregnancy and obstetric complications, stress and trauma, drug use, and genes, to increased presynaptic striatal dopaminergic function.
Journal ArticleDOI
Practice guideline for the treatment of patients with schizophrenia
Marvin I. Herz,Robert Paul Liberman,T. H. McGlashan,Jeffrey A. Lieberman,Richard Jed Wyatt,Stephen R. Marder,P. Wang,C. Allgulander,Ross J. Baldessarini,R. Balon,A. S. Bellack,C M Jr Berlin,C. H. Blackington,Peter F. Buckley,D. G. Carlson,J. Cott,Francine Cournos,P. Desai,L. Dickstein,Wayne Fenton,W. A. Fisher,Lois T. Flaherty,R. Freedman,Marc Galanter,E. Galton,Rohan Ganguli,L. K. Garrettson,S. Goldfinger,L. S. Goldman,M. Z. Goldstein,T. R. Gordy,S. H. Gray,Monica R. Green,W. M. Greenberg,John G. Gunderson,L. L. Hall,E. Haller,E. Hanin,L. Hawkins,T. W. Hester,T. Horn,J. K. Hsiao,N. V. Juthani,John M. Kane,A. Kayser,H. D. Kibel,R. A. Kimmich,R. R. Koegler,J. Krajeski,T. Kuehnel,J.S. Lamberti,Anthony F. Lehman,J. Leunello,R. L. Martin,R. McCarley,Mark McGee,Herbert Y. Meltzer,M.-Marsel Mesulam,Jeffrey L. Metzner,Loren R. Mosher,J. A. Motto,Kim T. Mueser,R. A. Munoz,H. A. Nasrallah,J. W. Newcomer,Lewis A. Opler,G. N. Peterson,M. Rapaport,Michelle Riba,V. I. Rickert,A. Rifkin,J. S. Rivenbark,S. Robertson,P. Ruiz,W. G. Ryan,M. O. Sanderson,R. B. Schiffer,P. M. Schyve,R. H. Sebring,W. W. Shen,D. Shore,G. M. Simpson,H. E. Soufi,L. I. Stein,N. Stotland,J. Strauss,D. Sundberg,D. Svendsen,Mauricio Tohen,M. Tsuang,J. G. Wagnitz,Richard D. Weiner,W. D. Weitzel,L. J. Wilkerson,D. Wingerson,C A Jr Zarate,J. Zito,Howard Zonana +97 more
Journal ArticleDOI
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Nancy C. Andreasen,William T. Carpenter,John M. Kane,Robert A. Lasser,Stephen R. Marder,Daniel R. Weinberger +5 more
TL;DR: The first consensus-based operational criteria for symptomatic remission in schizophrenia are based on distinct thresholds for reaching and maintaining improvement, as opposed to change criteria, allowing for alignment with traditional concepts of remission in both psychiatric and nonpsychiatric illness.
Journal ArticleDOI
Chlorpromazine equivalent doses for the newer atypical antipsychotics
TL;DR: These equivalency estimates may be useful for clinical and research purposes and the source of the dose equivalency estimation is evidence-based and consistent across medication.